Carcinoid Cancer Foundation Releases New Video Series Beginning with “The ABC’s of Carcinoid/NETs”
What is the most common kind of neuroendocrine tumor (NET)? How do these tumors grow? What is carcinoid syndrome? What are the quality of life issues for patients? In “The ABC’s of Carcinoid/NETs,” three of the world’s leading carcinoid and NET cancer…READ MORE
Cycling the C&O Canal for Carcinoid
When Diane and Dwight Mikulis cycle the 184 miles of the Chesapeake & Ohio Canal this summer, they will bring greater awareness to the rare cancer that Diane’s mother, Stella Mae Lux Behers, battled for six years after being diagnosed in 1996. Like …READ MORE
FDA Approves Amendment for PRRT Clinical Trial in Texas
BREAKING NEWS: The Food and Drug Administration (FDA) has just approved the RadioIsotope Therapy of America (RITA) Foundation’s amendment to the Investigational New Drug (IND) protocol for intra-hepatic artery administration of Lu-177 Octreotate…READ MORE
First Mobile App for Carcinoid and Neuroendocrine Cancer Community Goes Live
The first mobile app for carcinoid cancer and neuroendocrine tumor (NET) patients is now available for downloading on the iPhone, iPad, and Android! My NET Manager, a free app provided by Novartis Oncology, offers patients a unique opportunity to track…READ MORE
National Carcinoid and NET Patient Conference: Have You Registered?
Have you registered for the national carcinoid and NET patient conference in New Orleans, September 20 – 22? The hotel is over 90% booked and registration is nearing capacity! This is a wonderful opportunity to learn more about carcinoid and …READ MORE
More Things Zebra for the Carcinoid and Neuroendocrine Tumor (NET) Community: From the Everyday to the Extraordinary
Why the zebra for carcinoid and neuroendocrine cancer awareness? In medical school, students are told, “When you hear hoof beats, think horses, not zebras.” Physicians are taught to focus on the most likely possibilities when making a diagnosis,…READ MORE
Social Media Connects Carcinoid and Neuroendocrine Cancer Survivors
Denise Passehl, a carcinoid cancer survivor, will share her experience with social media when she participates in the 140 Characters Conference on April 23 in Des Moines, Iowa. The focus of the conference, designed by Jeff Pulver, is how “real time technology…READ MORE
Lexicon Pharmaceuticals Granted Orphan Drug Designation by FDA for Carcinoid Syndrome Treatment
Lexicon Pharmaceuticals, Inc. has been granted Orphan Drug Designation for telotristat etiprate (LX1032) by the U.S. Food and Drug Administration (FDA). LX1032 is used to treat carcinoid syndrome, a chronic condition caused by neuroendocrine tumors,…READ MORE
2012 National Carcinoid & NET Patient Conference: Register Today!
Carcinoid and NET (neuroendocrine tumor) cancer patients, caregivers, and family members have a unique opportunity to learn more about NET cancer, including the latest information about diagnosis and treatments, and to network with hundreds of others…READ MORE
Twitter Chat on Rare Disease Day to Focus on Carcinoid and NET Cancers
Join us on Rare Disease Day, February 29th, for a Twitter chat about NET (neuroendocrine tumor) cancers with Steven K. Libutti, MD, Director of Montefiore Einstein Center for Cancer Carein New York. The chat will begin at 2 pm, Eastern Time.
Follow @MontefioreNews…READ MORE